Ignite Creation Date:
2025-12-25 @ 1:46 AM
Ignite Modification Date:
2026-02-25 @ 5:50 PM
Study NCT ID:
NCT02253394
Status:
TERMINATED
Last Update Posted:
2019-11-15
First Post:
2014-09-17
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study
Sponsor:
Brigham and Women's Hospital
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Pulmonary Arterial Hypertension | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Pulmonary Arterial Hypertension (PAH) | View |
| None | Ambrisentan | View |
| None | Spironolactone | View |
| None | Selective Endothelin A (ETA) inhibition | View |
| None | Aldosterone antagonism | View |
| None | Cardiac output (CO) | View |
| None | Right ventricular (RV) function | View |
| None | Heart failure | View |
| None | Quality of life | View |
| None | Pro-inflammatory cytokine | View |
| None | Interleukin-6 (IL-6) | View |
| None | Troponin-I | View |
| None | N-terminal pro-brain natriuretic peptide (NT-BNP) | View |
| None | Collagen metabolism | View |
| None | N-terminal procollagen type I | View |
| None | Collagen III | View |
| None | Echocardiography | View |
| None | WHO Functional Class | View |
| None | Cardiopulmonary Exercise Test with Innocor | View |
| None | Peak oxygen consumption (pVO2) | View |
| None | Liver function markers (AST/ALT) | View |
| None | Renal function markers (creatinine and potassium) | View |